Mid Atlantic Bio Angels Invests in New View Surgical
ET | Source: Mid Atlantic Bio Angels
NEW YORK, Nov. 07, 2017 (GLOBE NEWSWIRE) — Mid Atlantic Bio Angels (MABA) announces today that it has made an investment in Boston-based New View Surgical., which has developed a proprietary surgical imaging system for laproscopic surgery. This is the eighth investment made by MABA since its founding.
“Laproscopic and minimally invasive surgeries have become the norm, and it is important that physicians have the most updated technology to both improve outcomes through enhanced control, while hospitals are given the opportunity to continue to minimize costs,” said Yaniv Sneor, a MABA co-founder and president of Blue Cactus Consulting. “We have been impressed with New View Surgical’s technology and management, and believe they offer solutions that will help bring laproscopic surgeries to the next level.”
New View Surgical is an early-stage surgical visualization company focused on the development and commercialization of the VisionPort™ System, a novel surgical imaging system for minimally invasive surgery. The company’s proprietary VisionPort™ system combines four instruments into one and is being developed as a disposable device. It enters as a trocar, functions as a laparoscope and deploys as a camera and an instrument channel. The key advantage of VisionPort over current visualization systems is that, for the first time, it gives the primary surgeon total control of both the instruments and visualization. The system provides a full, straight-on view of the tissue and instrument tips at all times, limiting accidental injury to adjacent organs as well as lowering the surgeon’s skill threshold and ergonomic stress. For more information please visit www.newviewsurg.com or follow the company on Twitter at @NewViewSurg.
“The New View Surgical team is very pleased to have multiple MABA members participate in our Series A round. The investments from MABA support the further development of our VisionPort™ System and our team’s mission to improve the safety, efficiency and cost profile of today’s surgical visualization equipment,” said Bryce Klontz, president and CEO of New View Surgical. “The memberships’ overall focus on the life-sciences also offers us a strong group of sophisticated investors with whom our team can network throughout the critical months ahead.”
About 1st Pitch Life Science
At a 1stPitch event (http://www.1stpitchlifescience.com), early stage life sciences and healthcare companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience Q&A. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1stPitch are invited to hear the panel constructively critique the company’s presentation, business model and perceived viability in the market.
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA’s goal is to create an environment where the depth of investors’ knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.